SBIR Phase II: Fluorescent Polymeric Nanoparticles

这个小企业创新研究（SBIR）第二阶段项目将开发基于聚（苯撑乙炔（PPE））纳米颗粒的新一代荧光放大试剂。由于放大聚合物在这些化合物的增强灵敏度中的作用，这些化合物被称为放大剂试剂。该项目将开发和推出两种类型的Amplimer试剂：微阵列和定量PCR试剂。Amplimer试剂将通过提供更亮、更稳定的荧光信号以及通过荧光放大效应提高灵敏度来提高基于荧光的测定的灵敏度和性能。这项技术的商业和更广泛的影响是可消耗的荧光试剂，提高了两个快速增长的基因序列分析诊断平台的灵敏度和可靠性：基于微阵列的测定和定量PCR测定。基于基因序列信息的诊断目前占240亿美元诊断市场的10亿美元。随着人类基因组计划的后续工作渗透到药物发现和医学科学中，这一数字预计将大幅增长。

This Small Business Innovation Research (SBIR) Phase II project will develop a new generation of fluorescence amplifying reagents based on poly (phenylene ethynylene (PPE)) nanoparticles. Because of the role of the amplifying polymer in the enhanced sensitivity of these compounds, these compounds are called Amplimer reagents. The project will develop and launch two types of Amplimer reagents: microarray and quantitative PCR reagents. The Amplimer reagents will improve the sensitivity and performance of fluorescence-based assays by providing brighter, more stable fluorescence signals and by improving sensitivity through fluorescence amplification effects. The commercial and broader impacts of this technology are consumable fluorescent reagents that improve the sensitivity and reliability of two rapidly growing diagnostic platforms for genetic sequence analysis: microarray-based assays and quantitative PCR assays. Diagnostics based on genetic sequence information currently account for $1 billion of the $24 billion dollar diagnostics market. This figure is expected to grow significantly as the follow-on of the human genome project filters through drug discovery and medical science.